Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

PURPOSE: The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected stage IIIC and IV melanoma patients. EXPERIMENTAL DESIGN: HLA-A*0201 positive patients with...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Gibney, Geoffrey T., Kudchadkar, Ragini R., DeConti, Ronald C., Thebeau, Melissa S., Czupryn, Maria P., Tetteh, Leticia, Eysmans, Cabell, Richards, Allison, Schell, Michael J., Fisher, Kate J., Horak, Christine E., Inzunza, H. David, Yu, Bin, Martinez, Alberto J., Younos, Ibrahim, Weber, Jeffrey S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4620684/
https://ncbi.nlm.nih.gov/pubmed/25524312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2468
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia